FemTech Applications in Menopause Management

Start with the supply side, because everything downstream follows from it. As of 2024, 80 percent of OB-GYNs lacked formal menopause training. A survey published in Menopause found that only 31.6 percent of OB-GYN residency programs included menopause medicine as of 2023. The specialists women are most likely to turn to are, structurally, unprepared for this conversation.

The treatment gap compounds the training gap. Roughly three quarters of perimenopausal women experience vasomotor symptoms: the hot flashes, night sweats, and thermoregulatory disruptions that are the most widely recognized hallmarks of the transition. Only 4 to 6 percent currently use hormone therapy. Not because hormone therapy lacks efficacy. Partly because a widely publicized misreading of Women's Health Initiative data from the early 2000s cast a long shadow over HRT's reputation, and clinicians already undertrained in menopause medicine have been slow to rehabilitate it. Then add the access barriers: as of 2025, only Illinois and Louisiana mandate insurance coverage of medically necessary menopause treatment across both public and private insurers. Everywhere else, coverage is fragmented, inconsistent, or absent.

These are not incidental oversights. They explain why women arrive at apps and telehealth platforms as a first resort rather than a last one. FemTech in menopause care is largely the product of that necessity, and understanding that context matters when you are evaluating whether a given tool is filling a genuine clinical void or simply adding a convenience layer to a system that already functions. For most menopausal women, it is the former.

The Economic Weight That Makes Menopause a Public Health and Employer Issue

Menopause is not just a healthcare problem. It is an economic one, and the numbers are now large enough that employers, insurers, and governments have started paying attention in ways they simply were not five years ago.

Mayo Clinic Proceedings research, cited through the Stanford Institute for Economic Policy Research, puts menopause-related productivity losses in the U.S. at $1.8 billion annually. Healthcare expenses add another $24.8 billion. The combined U.S. burden sits at approximately $26.6 billion per year. RAND Corporation analysis found that roughly 600,000 women have left the U.S. workforce due to menopausal symptoms. Globally, an AARP survey estimated worker productivity losses at $150 billion. In the U.K., the annual loss to workforce participation runs to roughly £10 billion.

When symptoms cost employers measurable output, employers have financial incentive to fund solutions. When healthcare expenses at that scale appear in actuarial tables, insurers have reason to cover prevention and management tools. The capital flowing into menopause FemTech is not purely altruistic; it is rational allocation in response to a documented economic burden. Funding rooted in quantifiable loss is considerably more durable than funding rooted in trend-driven venture enthusiasm, which is relevant to anyone wondering whether this space will still exist in ten years.

How a Once-Overlooked FemTech Segment Became Its Fastest-Growing Vertical

Menopause care FemTech was valued at $3.04 billion in 2024 and is projected to reach $7.45 billion by 2030 at a compound annual growth rate of 16.2 percent, according to Grand View Research. The broader FemTech market was estimated at $39.29 billion in 2024 and projected to reach $97.25 billion by 2030. Analyst estimates across firms vary substantially. The consistent signal is rapid growth, not any single number.

Where investment is actually going tells a more interesting story than the headline figures. Only about 7 percent of FemTech startups currently focus on menopause. The vertical is the fastest-growing but still underfunded relative to its user base. Per Dealroom data through mid-2026, menopause tops the FemTech sub-sector ranking by investment momentum, with venture capital into the space up 9 percent over three years to $104 million in 2025, and one unicorn formed. Dedicated menopause startups raised over $200 million across 2022 to 2025 as investors recognized a global market opportunity reaching 1.1 billion women.

The structural repositioning underneath those numbers is worth sitting with. FemTech as a category originated largely in reproductive wellness and passive period tracking: ovulation calendars, cycle logs, fertility predictions. Menopause is a different animal entirely. The users are older, the clinical complexity is greater, the interventions are more medically substantive, and the stakes are considerably higher. Menopause FemTech is where the sector either proves it can handle clinical longevity or reveals that it was always better suited to lifestyle logging. That question is still being answered.

What Symptom-Tracking Apps Actually Give Women to Work With Day to Day

The core function of a symptom-tracking app sounds almost deceptively mundane: log what you are experiencing over time and let patterns surface that a single clinical appointment would miss. But that function is genuinely valuable, because the subjective, diffuse nature of menopause symptoms is one of the primary reasons they get dismissed in clinical settings. A woman who walks in saying she is exhausted and not sleeping well and having mood swings is easy to wave away. A woman who walks in with six months of structured longitudinal data is considerably harder to dismiss. An app transforms lived experience into something a clinician can actually read. That changes what is possible in a fifteen-minute appointment, not because the appointment gets longer, but because the patient arrives having already done the diagnostic groundwork.

Several platforms have differentiated themselves on how they handle that data. Balance holds ORCHA certification, a quality accreditation framework for digital health tools, and combines period tracking with mood and medication logging to produce downloadable health reports women can bring directly to clinical appointments. Olivia takes a therapeutic approach, building cognitive behavioral therapy techniques into its structure so that rather than logging symptoms as neutral data points, women use CBT-based frameworks to identify triggers, reframe responses, and work through mood and physical symptoms with structured programs. Midday, developed through a collaboration involving SRI International, Lisa Health, and Mayo Clinic, integrates mental health check-ins, expert-written educational content, and hormone therapy decision support drawn from Mayo Clinic's clinical resources, and syncs with wearables. Flo Health is expanding its perimenopause feature set to retain its 70 million users as they age through the transition; Flo became the first FemTech application to achieve unicorn status following a $200 million funding round in 2024, and its menopause expansion represents the large-platform strategy of embedding perimenopause tools into an existing reproductive health user base rather than building from scratch.

Tracking apps give women language and data, reduce the isolation that comes from experiencing symptoms that feel invisible or socially unspeakable, and enable a kind of longitudinal self-awareness that episodic clinical encounters cannot replicate. They do not produce diagnosis or treatment. The adjacent tools, hormone monitoring, wearables, and telehealth, exist precisely because tracking alone is not the full answer.

What At-Home Hormone Monitoring Adds and Where It Stops Short

In 2024, Mira Care launched its Menopause Transitions Kit: an AI-powered at-home device that tracks four key reproductive hormones, positioning hormone data as a personalization layer for navigating perimenopause. Moving from self-reported symptoms to measured biological signals is, in principle, a step toward clinical-grade data in a consumer product.

The distinction matters more than it initially appears. A symptom log tells you how you feel. A hormone reading tells you something about why, or at least offers a biological correlate. For women who have spent years being told their symptoms are stress or aging or imagination, having a measurable number to point to can be clarifying in ways that are hard to overstate.

But at-home hormone tests are not diagnostic tools, and interpreting perimenopause hormone levels is genuinely complex. Levels do not follow a linear decline; they fluctuate irregularly over years, and the clinical significance of any single reading depends on context that a consumer device cannot supply. A number without interpretive scaffolding can increase anxiety rather than reduce it, and that is a real risk.

The value of at-home hormone monitoring scales directly with what happens downstream. If the data feeds into a conversation with a menopause-literate clinician, it is useful. If it sits in an app dashboard without clinical interpretation, its utility is limited. That gap between having the number and knowing what to do with it is precisely where telehealth integration stops being optional.

How Wearables Detect Physiological Changes Women Have Not Yet Consciously Noticed

One of the more quietly remarkable things wearables can do in this context is detect measurable physiological changes before a woman is consciously aware of them. Declines in heart-rate variability, resting heart-rate spikes correlating with hot flash events, sleep architecture disruptions, skin-temperature fluctuations: these are signals that consumer wearables now have the sensor resolution to capture. They correlate with underlying hormonal shifts, and continuous passive monitoring over weeks and months builds a baseline against which deviations become visible in ways that a snapshot hormone test or a manually logged symptom simply cannot replicate. You cannot log what you have not noticed. A wearable running around the clock does not have that problem.

Several companies are active here. Oura, Clue, Mira Care, Amira, and Whoop are all tracking menopause-relevant biometrics, with several partnering with research institutions to develop their analytical frameworks. Oura's work is the most publicly documented at scale: the company drew on aggregated data from over 100,000 female Oura members on perimenopause to inform its August 2025 launch of a perimenopause check-in feature designed to surface early-stage symptoms and connect users with expert guidance.

The clinical interest in continuous biometric data is legitimate. A passive sensor captures the variability and temporal patterns that matter for understanding menopause physiology in ways that periodic testing cannot. But consumer wearable signals have not yet been validated as a clinical diagnostic standard for menopause in peer-reviewed trials at a scale that would support definitive conclusions. Raw biometric scores, absent interpretive context, are at best interesting and at worst a source of anxiety without actionable guidance. The wearable is most useful when its data feeds somewhere with a human qualified to read it.

What Telehealth Menopause Platforms Deliver That Apps Alone Cannot

Here is the category distinction that matters most: telehealth platforms deliver diagnosis, prescriptions, and individualized treatment plans. A woman who needs hormone therapy, non-hormonal pharmacological options, or a structured clinical program needs a licensed clinician. No logging interface, however sophisticated, changes that.

Several platforms have emerged as meaningful players, each with a distinct approach. Midi Health raised $65 million across two funding rounds in 2024 to scale virtual menopause care, committing to substantial clinician expansion and extending insurance coverage to all 50 U.S. states; in late 2025, Midi raised a further $50 million Series C to build an AI-powered women's health information tool, making it the largest dedicated platform in the category by capitalization and clinical scale. Evernow operates on a cash-pay subscription model with asynchronous physician consultations, shipping FDA-approved estradiol, progesterone, and combination products monthly, prioritizing access speed over insurance integration. Alloy secured $16 million in Series A funding in November 2024 to expand telehealth services for midlife women.

Elektra Health bundles clinical care with structured menopause education, targeting women who want to understand the physiology behind their symptoms rather than simply receive a prescription. In October 2025, Elektra launched HelloMeno in partnership with Oscar Health: a menopause-focused ACA health plan available in 11 states beginning January 2026. Embedding menopause care into an insurance product rather than selling it as a subscription or cash-pay service directly addresses the coverage barrier that has kept so many women out of the system, and it represents a different logic than the rest of the market. Most FemTech menopause platforms solve the access problem by making care faster or more convenient within the existing payment structure. HelloMeno changes the underlying structure. If that model scales and replicates, it would be the most meaningful access shift this space has seen.

The limitations of the telehealth category are also real. Cash-pay models, however fast and clinically excellent, exclude lower-income women. Insurance coverage remains patchy outside the platforms that have done the hard work of contracting with carriers. And the degree to which AI-powered tools augment versus substitute clinical judgment is a question the industry is still working through, with significant implications for quality of care.

What the Research Currently Says About Whether These Tools Improve Outcomes

The evidence base for digital menopause tools is still early. Most published research is industry-sponsored, conducted over short durations, or uses self-reported symptom scales rather than clinical endpoints. Read efficacy claims carefully and distinguish between "users report feeling better" and "a randomized controlled trial demonstrated measurable clinical improvement." Those are not the same claim.

The strongest evidence in this space belongs to CBT-based digital interventions, for the straightforward reason that cognitive behavioral therapy for menopause has decades of clinical research behind it predating any app. Platforms like Olivia that implement structured CBT programs are building on a validated therapeutic framework. The digital delivery is newer; the underlying approach is not, and that distinction matters when evaluating what you are actually getting.

Wearable and biometric data research is in an active accumulation phase. Oura's 100,000-member dataset is meaningful for exploratory analysis, and the research emerging from it is substantive. But wearable signals have not been validated against clinical menopause diagnostics in peer-reviewed trials at a scale that would support regulatory-grade conclusions. At-home hormone monitoring has value that scales with clinical interpretation. The number itself is not the outcome.

Telehealth platforms show the most direct pathway to measurable health outcomes precisely because they connect data layers to licensed clinicians who can act on what they see. Apps and wearables are most valuable as data-gathering infrastructure when they feed that clinical relationship. Isolated from it, they remain useful but bounded.

For a woman evaluating specific tools: clinical partnerships, such as those with Mayo Clinic or Oscar Health, and regulatory certifications like ORCHA accreditation, are meaningful quality signals. Marketing language about "personalized care" should be tested against one concrete question: is a licensed clinician in the loop, reviewing data and making clinical decisions? If yes, that claim has weight. If no, it is a UX feature dressed up as medicine.

How to Read the FemTech Menopause Landscape as a Woman Deciding What to Use

The product categories that exist right now form a rough capability hierarchy: symptom tracking, continuous biometric monitoring, at-home hormone data, and telehealth with prescribing clinicians. These are complementary layers, not competing options. The right combination depends on where a woman is in the menopause transition and what she actually needs.

A woman in perimenopause, noticing changes but not yet seeking treatment, benefits most from tracking tools. They build the symptom history that makes a clinical appointment productive, surface patterns she would otherwise attribute to unrelated causes, and give her the vocabulary and data to advocate for herself when she does seek care. That last part is not trivial. Walking into a clinical encounter with documentation changes the dynamic of the conversation in ways that are difficult to manufacture otherwise.

A woman who needs treatment, whether hormone therapy, non-hormonal pharmacological options, or a structured therapeutic program, requires a telehealth platform with licensed clinicians. An app that cannot prescribe cannot treat. The mistake to avoid is substituting data collection for clinical care when clinical care is what the situation calls for.

Quality signals worth scrutinizing: clinical partnerships or institutional backing, ORCHA certification, insurance acceptance, and transparency about whether a licensed provider is reviewing data and making clinical decisions. These are not foolproof filters, but they are considerably more reliable than testimonials or user counts.

The coverage and cost reality remains uneven. Cash-pay telehealth platforms offer the fastest access but are not universally affordable. The HelloMeno ACA plan model, if it proves out and scales, represents the most structurally significant access expansion the category has produced. Whether other carriers and platforms follow that blueprint is the most consequential open question in the space right now, and the answer will determine whether FemTech menopause care becomes a broadly accessible system or a well-designed solution for women who were already resourced enough to find their way.